Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

Market Overview: The European CRISPR gene editing market has experienced significant expansion, driven by advancements in biotechnology and increasing investment in genetic research. With a compound ...

The North America CRISPR gene editing market is poised for substantial growth, with projections indicating a robust annual expansion of 24.4% throughout the forecast period. By 2031, it is anticipated ...

IntroductionThe Global Plasmid DNA Manufacturing Market is poised for significant growth, with a valuation of USD 2.13 ...

The global gene therapy market is projected to grow at a significant CAGR of 20% from 2024 to 2029. This growth is driven by ...

A research team has developed an advanced delivery system that transports gene-editing tools based on the CRISPR/Cas9 gene-editing system into living cells with significantly greater efficiency ...

today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into Vita's cell therapeutic programs. This nonexclusive sublicense grants Vita Therapeutics ...

Key Laboratory of Quality and Safety Control of Citrus Fruits, Ministry of Agriculture and Rural Affairs, Southwest University, Chongqing 400712, P.R. China National Citrus Engineering Research Center ...

REDWOOD CITY, Calif., April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into ...

First, we investigated the critical open chromatin region to control the transcription initiation of henna. Then, we proved its regulatory activity of chromatin openness by using cell line experiments ...